A Cohort Establishment Study of Total Management of Ovarian Cancer (Including Fallopian Tube Cancer and Primary Peritoneal Cancer)
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Tumor of Female Reproductive System
- Sponsor
- Sichuan Cancer Hospital and Research Institute
- Enrollment
- 500
- Locations
- 1
- Primary Endpoint
- Progress Freesurvival (PFS)
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
A cohort establishment study of total management of ovarian cancer (including fallopian tube cancer and primary peritoneal cancer).
Detailed Description
1. To investigate the effects of surgery, chemotherapy, maintenance therapy and related factors on the prognosis and quality of life of patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer); 2. To study the postoperative recovery of patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer), perioperative complications, adverse reactions after chemotherapy, adverse reactions during targeted drug maintenance therapy, and explore possible effective preventive measures; 3. The prognostic factors of ovarian cancer (including fallopian tube cancer and primary peritoneal cancer) were analyzed; 4. To study the efficacy and safety of PARPi in clinical application in patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer).
Investigators
Dengfeng Wang
Deputy chief
Sichuan Cancer Hospital and Research Institute
Eligibility Criteria
Inclusion Criteria
- •Patients diagnosed with ovarian cancer (including fallopian tube cancer, primary peritoneal cancer) and intended to be treated in our hospital;
- •Can cooperate with later follow-up.
Exclusion Criteria
- •Patients with other malignant tumors or previous history of other malignant tumors;
- •Have cognitive impairment.
Outcomes
Primary Outcomes
Progress Freesurvival (PFS)
Time Frame: Average six months after study completion.
The time from the start of treatment until the patient progresses further or dies.
Overall Survival (OS)
Time Frame: Average six months after study completion.
Measure the time from the start of treatment to the time of death.
Secondary Outcomes
- Occurrence of adverse reactions(Average six months after study completion.)